IMNM
Immunome Inc

2,049
Mkt Cap
$1.62B
Volume
850,207.00
52W High
$18.79
52W Low
$5.15
PE Ratio
-5.98
IMNM Fundamentals
Price
$17.51
Prev Close
$17.69
Open
$18.00
50D MA
$14.06
Beta
1.31
Avg. Volume
1.27M
EPS (Annual)
-$5.00
P/B
6.15
Rev/Employee
$76,618.64
Loading...
Loading...
News
all
press releases
Immunome (NASDAQ:IMNM) Hits New 1-Year High on Analyst Upgrade
Immunome (NASDAQ:IMNM) Sets New 52-Week High After Analyst Upgrade...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
318,086 Shares in Immunome, Inc. $IMNM Purchased by Candriam S.C.A.
Candriam S.C.A. bought a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission...
MarketBeat·4d ago
News Placeholder
Immunome (NASDAQ:IMNM) Stock Price Up 8.6% - Here's Why
Immunome (NASDAQ:IMNM) Trading 8.6% Higher - Here's What Happened...
MarketBeat·5d ago
News Placeholder
Immunome (NASDAQ:IMNM) Hits New 12-Month High - What's Next?
Immunome (NASDAQ:IMNM) Reaches New 52-Week High - Here's Why...
MarketBeat·7d ago
News Placeholder
Nan Fung Trinity HK Ltd. Invests $5.10 Million in Immunome, Inc. $IMNM
Nan Fung Trinity HK Ltd. acquired a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired...
MarketBeat·7d ago
News Placeholder
Immunome (NASDAQ:IMNM) Announces Earnings Results
Immunome (NASDAQ:IMNM - Get Free Report) posted its earnings results on Thursday. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had...
MarketBeat·11d ago
News Placeholder
Immunome (NASDAQ:IMNM) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded shares of Immunome from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·11d ago
News Placeholder
Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush
Wedbush restated an "outperform" rating and issued a $21.00 target price on shares of Immunome in a research report on Friday...
MarketBeat·12d ago
News Placeholder
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended...
Business Wire·14d ago
News Placeholder
Immunome (IMNM) Expected to Announce Earnings on Wednesday
Immunome (NASDAQ:IMNM) will be releasing its Q3 2025 earnings before the market opens on Wednesday, November 12. (View Earnings Report at...
MarketBeat·14d ago

Latest IMNM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.